SAN DIEGO & ALISO VIEJO, Calif.--(BUSINESS WIRE)--MicroVention, Inc., a global neurovascular company and wholly owned subsidiary of Terumo Corporation, announced the publication of WEB-IT 5-year ...

The WEB-IT pivotal trial highlights positive clinical outcomes with the WEB® Aneurysm Embolization System, the only intrasaccular flow disruptor approved in the United States. The WEB ® system ...

MicroVention is Also Celebrating the Five-Year Anniversary of its WEB™ Aneurysm Embolization System with more than 10,000 Units Sold in the United States COLORADO SPRINGS, Colo. & ALISO VIEJO, Calif., ...

Terumo Corporation’s (TRUMY) wholly-owned subsidiary MicroVention, Inc. recently announced the publication of the Clinical Evaluation of WEB 17 Device in Intracranial Aneurysms (CLEVER) study results.

ALISO VIEJO, Calif. & ALAJUELA, Costa Rica--(BUSINESS WIRE)--#CostaRica--MicroVention, Inc., a global neurovascular company and wholly owned subsidiary of Terumo Corporation, today hosted the Republic ...

MicroVention Inc., OC’s sixth-largest device maker by local employee count with 1,200 area workers, named Carsten Schroeder chief executive and president, beginning early November. Schroeder comes to ...

ALISO VIEJO, Calif., April 18, 2019 /PRNewswire/ -- MicroVention, Inc., a U.S.-based subsidiary of Terumo Corporation and a global neurovascular company, announced today the publication of the WEB-IT ...